ArticleFrontiers in endocrinology2026
Development and validation of an explainable machine learning model for predicting interstitial fibrosis and tubular atrophy in biopsy-confirmed diabetic nephropathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interstitial fibrosis and tubular atrophy (IFTA) are key pathological features of chronic kidney damage and progression in diabetic nephropathy (DN). Early identification of patients at higher risk of IFTA may support risk stratification, although reliable non-invasive tools remain limited. This study aimed to develop and validate machine learning (ML) models for predicting IFTA in patients with biopsy-confirmed DN. Methods: In this retrospective study, 232 patients with biopsy-confirmed DN from 2017 to 2025 were included and randomly divided into a training cohort ( Results: Seven predictors were identified, including diabetic retinopathy, age, proteinuria, estimated glomerular filtration rate (eGFR), triglycerides, duration of diabetes, and hemoglobin. Among the models, XGBoost achieved the highest AUC in the validation cohort, with an area under the curve (AUC) of 0.759, accuracy of 72.1%, sensitivity of 92.3%, specificity of 44.8%, and F1 score of 79.1%. Overall, the model showed moderate discrimination, with high sensitivity but limited specificity, suggesting potential value for exploratory risk screening rather than definitive clinical use. SHAP analysis indicated that higher proteinuria, triglycerides, presence of diabetic retinopathy, and longer diabetes duration, together with lower eGFR, hemoglobin, and younger age, were associated with an increased predicted risk of IFTA. Conclusion: ML models, particularly XGBoost, showed moderate performance in predicting IFTA in patients with biopsy-confirmed DN using routinely available clinical variables. These findings support the feasibility of an interpretable, non-invasive approach for exploratory risk estimation of tubulointerstitial injury. However, because of the modest sample size, limited specificity, relatively high false positive rate, and lack of external validation, the present results should be considered preliminary and require further validation before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.